The European Medicines Agency recently approved the marketing of bevacizumab-vikg for the treatment of wet age-related macular degeneration. The drug has shown significant efficacy in clinical trials, with a higher percentage of patients gaining visual acuity compared to other approved medications. The safety profile of the drug was reported to be consistent with previous studies, with few adverse events. The approval comes after controversy over the off-label use of bevacizumab for AMD due to its lower cost compared to other approved drugs. Outlook Therapeutics plans to conduct further trials to assess the drug’s efficacy in other retinal diseases.
Source link
EMA Approves Ocular Formulation of Bevacizumab
